Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation

od Dimou, Anastasios, Ou, Sai-Hong I., Doebele, Robert C.
Izdano u JCO Precis Oncol (2019)

Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S...

od Arnold, Susanne M., Moon, James, Williamson, Stephen K., Atkins, James N., Ou, Sai-Hong I., LeBlanc, Michael, Urba, Susan G.
Izdano 2009

Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity

od Zhang, Zhushan, Huang, Tai-Qin, Nepliouev, Igor, Zhang, Hengtao, Barnett, Adam S., Rosenberg, Paul B., Ou, Sai-Hong I., Stiber, Jonathan A.
Izdano u Cardiooncology (2017)

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

od Costa, Daniel B., Shaw, Alice T., Ou, Sai-Hong I., Solomon, Benjamin J., Riely, Gregory J., Ahn, Myung-Ju, Zhou, Caicun, Shreeve, S. Martin, Selaru, Paulina, Polli, Anna, Schnell, Patrick, Wilner, Keith D., Wiltshire, Robin, Camidge, D. Ross, Crinò, Lucio
Izdano u J Clin Oncol (2015)

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

od Farago, Anna F., Le, Long P., Zheng, Zongli, Muzikansky, Alona, Drilon, Alexander, Patel, Manish, Bauer, Todd M., Liu, Stephen V., Ou, Sai-Hong I., Jackman, David, Costa, Daniel B., Multani, Pratik S., Li, Gary G., Hornby, Zachary, Chow-Maneval, Edna, Luo, David, Lim, Jonathan E., Iafrate, Anthony J., Shaw, Alice T.
Izdano u J Thorac Oncol (2015)

Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an NTRK Gene Fusion

od Farago, Anna F., Taylor, Martin S., Doebele, Robert C., Zhu, Viola W., Kummar, Shivaani, Spira, Alexander I., Boyle, Theresa A., Haura, Eric B., Arcila, Maria E., Benayed, Ryma, Aisner, Dara L., Horick, Nora K., Lennerz, Jochen K., Le, Long P., Iafrate, A. John, Ou, Sai-Hong I., Shaw, Alice T., Mino-Kenudson, Mari, Drilon, Alexander
Izdano u JCO Precis Oncol (2018)

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis

od Awad, Mark M., Leonardi, Giulia C., Kravets, Sasha, Dahlberg, Suzanne E., Drilon, Alexander, Noonan, Sinead A., Camidge, D. Ross, Ou, Sai-Hong I., Costa, Daniel B., Gadgeel, Shirish M., Steuer, Conor E., Forde, Patrick M., Zhu, Viola W., Fukuda, Yoko, Clark, Jeffrey W., Jänne, Pasi A., Mok, Tony, Sholl, Lynette M., Heist, Rebecca S.
Izdano u Lung Cancer (2019)

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

od Shaw, Alice T., Ou, Sai-Hong I., Bang, Yung-Jue, Camidge, D. Ross, Solomon, Benjamin J., Salgia, Ravi, Riely, Gregory J., Varella-Garcia, Marileila, Shapiro, Geoffrey I., Costa, Daniel B., Doebele, Robert C., Le, Long Phi, Zheng, Zongli, Tan, Weiwei, Stephenson, Patricia, Shreeve, S. Martin, Tye, Lesley M., Christensen, James G., Wilner, Keith D., Clark, Jeffrey W., Iafrate, A. John
Izdano u N Engl J Med (2014)

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

od Shaw, Alice T, Yeap, Beow Y, Solomon, Benjamin J, Riely, Gregory J, Gainor, Justin, Engelman, Jeffrey A, Shapiro, Geoffrey I, Costa, Daniel B, Ou, Sai-Hong I, Butaney, Mohit, Salgia, Ravi, Maki, Robert G, Varella-Garcia, Marileila, Doebele, Robert C, Bang, Yung-Jue, Kulig, Kimary, Selaru, Paulina, Tang, Yiyun, Wilner, Keith D, Kwak, Eunice L, Clark, Jeffrey W, Iafrate, A John, Camidge, D Ross
Izdano 2011

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

od Hrustanovic, Gorjan, Olivas, Victor, Pazarentzos, Evangelos, Tulpule, Asmin, Asthana, Saurabh, Blakely, Collin M, Okimoto, Ross A, Lin, Luping, Neel, Dana S, Sabnis, Amit, Flanagan, Jennifer, Chan, Elton, Varella-Garcia, Marileila, Aisner, Dara L, Vaishnavi, Aria, Ou, Sai-Hong I, Collisson, Eric A, Ichihara, Eiki, Mack, Philip C, Lovly, Christine M, Karachaliou, Niki, Rosell, Rafael, Riess, Jonathan W, Doebele, Robert C, Bivona, Trever G
Izdano u Nat Med (2015)

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

od Camidge, D Ross, Bang, Yung-Jue, Kwak, Eunice L, Iafrate, A John, Varella-Garcia, Marileila, Fox, Stephen B, Riely, Gregory J, Solomon, Benjamin, Ou, Sai-Hong I, Kim, Dong-Wan, Salgia, Ravi, Fidias, Panagiotis, Engelman, Jeffrey A, Gandhi, Leena, Jänne, Pasi A, Costa, Daniel B, Shapiro, Geoffrey I, LoRusso, Patricia, Ruffner, Katherine, Stephenson, Patricia, Tang, Yiyun, Wilner, Keith, Clark, Jeffrey W, Shaw, Alice T
Izdano 2012

Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusio...

od Piotrowska, Zofia, Isozaki, Hideko, Lennerz, Jochen K., Gainor, Justin F., Lennes, Inga T., Zhu, Viola W., Marcoux, Nicolas, Banwait, Mandeep K., Digumarthy, Subba R., Su, Wenjia, Yoda, Satoshi, Riley, Amanda K., Nangia, Varuna, Lin, Jessica J., Nagy, Rebecca J., Lanman, Richard B., Dias-Santagata, Dora, Mino-Kenudson, Mari, Iafrate, A. John, Heist, Rebecca S., Shaw, Alice T., Evans, Erica K., Clifford, Corinne, Ou, Sai-Hong I., Wolf, Beni, Hata, Aaron N., Sequist, Lecia V.
Izdano u Cancer Discov (2018)

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

od Kwak, Eunice L., Bang, Yung-Jue, Camidge, D. Ross, Shaw, Alice T., Solomon, Benjamin, Maki, Robert G., Ou, Sai-Hong I., Dezube, Bruce J., Jänne, Pasi A., Costa, Daniel B., Varella-Garcia, Marileila, Kim, Woo-Ho, Lynch, Thomas J., Fidias, Panos, Stubbs, Hannah, Engelman, Jeffrey A., Sequist, Lecia V., Tan, WeiWei, Gandhi, Leena, Mino-Kenudson, Mari, Wei, Greg C., Shreeve, S. Martin, Ratain, Mark J., Settleman, Jeffrey, Christensen, James G., Haber, Daniel A., Wilner, Keith, Salgia, Ravi, Shapiro, Geoffrey I., Clark, Jeffrey W., Iafrate, A. John
Izdano 2010

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

od Skoulidis, Ferdinandos, Goldberg, Michael E., Greenawalt, Danielle M., Hellmann, Matthew D., Awad, Mark M., Gainor, Justin F., Schrock, Alexa B., Hartmaier, Ryan J., Trabucco, Sally E., Gay, Laurie, Ali, Siraj M., Elvin, Julia A., Singal, Gaurav, Ross, Jeffrey S., Fabrizio, David, Szabo, Peter M., Chang, Han, Sasson, Ariella, Srinivasan, Sujaya, Kirov, Stefan, Szustakowski, Joseph, Vitazka, Patrik, Edwards, Robin, Bufill, Jose A., Sharma, Neelesh, Ou, Sai-Hong I., Peled, Nir, Spigel, David R., Rizvi, Hira, Aguilar, Elizabeth Jimenez, Carter, Brett W., Erasmus, Jeremy, Halpenny, Darragh F., Plodkowski, Andrew J., Long, Niamh M., Nishino, Mizuki, Denning, Warren L., Galan-Cobo, Ana, Hamdi, Haifa, Hirz, Taghreed, Tong, Pan, Wang, Jing, Rodriguez-Canales, Jaime, Villalobos, Pamela A., Parra, Edwin R., Kalhor, Neda, Sholl, Lynette M., Sauter, Jennifer L., Jungbluth, Achim A., Mino-Kenudson, Mari, Azimi, Roxana, Elamin, Yasir Y., Zhang, Jianjun, Leonardi, Giulia C., Jiang, Fei, Wong, Kwok-Kin, Lee, J. Jack, Papadimitrakopoulou, Vassiliki A., Wistuba, Ignacio I., Miller, Vincent A., Frampton, Garrett M., Wolchok, Jedd D., Shaw, Alice T., Jänne, Pasi A., Stephens, Philip J., Rudin, Charles M., Geese, William J., Albacker, Lee A., Heymach, John V.
Izdano u Cancer Discov (2018)